Fusion proteins for the treatment of CNS
First Claim
Patent Images
1. A composition comprising:
- an isolated nucleic acid comprising a sequence that encodes a polypeptide, said polypeptide comprising;
a protein transduction domain, and a proteoglycan degrading domain, or a domain that promotes neural regeneration.
3 Assignments
0 Petitions
Accused Products
Abstract
This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.
102 Citations
45 Claims
-
1. A composition comprising:
an isolated nucleic acid comprising a sequence that encodes a polypeptide, said polypeptide comprising;
a protein transduction domain, and a proteoglycan degrading domain, or a domain that promotes neural regeneration.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
10. A composition comprising:
a polypeptide comprising at least two of;
a protein transduction domain, a proteoglycan degrading domain, or a domain that promotes neural regeneration.- View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19)
-
20. A method of promoting recovery of neurological function comprising:
-
identifying a patient having comprised neurological function characterized by an SCI injury; and administering a composition comprising at least two of;
a protein transduction polypeptide, a proteoglycan degrading polypeptide, or a polypeptide that promotes neural regeneration. to a patient in need of such treatment. - View Dependent Claims (21, 22, 23)
-
-
24. A method of facilitating diffusion of an agent in a central nervous system comprising:
-
administering the agent to the central nervous system; and modifying an extracellular matrix in the central nervous system to allow penetration of the agent into the extracellular matrix. - View Dependent Claims (25, 26, 27, 28, 29, 30, 31)
-
-
32. A method of penetration of an agent through an extracellular matrix, comprising:
administering at least one enzyme capable of cleaving chondroitin sulfate proteoglycans. - View Dependent Claims (33, 34, 35, 36, 37)
-
38. A method of enhancing uptake of an agent in a central nervous system, comprising:
administering the agent and at least one enzyme capable of cleaving chondroitin sulfate proteoglycans. - View Dependent Claims (39, 40, 41, 42, 43, 44, 45)
Specification